Amrutanjan Health Care Limited (AMRUTANJAN) fundamentals
Amrutanjan Health Care Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as AMRUTANJAN (ISIN INE098F01031). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Amrutanjan Health Care Limited does
Amrutanjan Health Care Limited is an India-based company, which is engaged in the business of manufacturing, supplying and sale of products in pain management, congestion management, beverages, and hygiene and services in pain management. Its segments include OTC Products, Women Hygiene, Beverages and Others. The OTC Products segment is engaged in manufacturing products for pain management, congestion management and hygiene. The Women Hygiene includes Comfy Snug Fit, Comfy Snug Fit Extra Long, and Comfy Snug Fit Ultra XL. The Beverages segment is engaged in manufacturing fruit juices and oral hydration drinks. The Others segment includes the pain management center. The Company’s pain management products include Pain Balm Extra Power, Strong Pain Balm, New Maha Strong Pain Balm, Roll on and Advanced Back Pain + Roll-On, among others. Its congestion management products include Relief Cold Rub, Relief Nasal Inhaler, Relief Cough Syrup and Relief Swas Mint.
Valuation and market data
| Last close | ₹493.35 |
|---|---|
| Market capitalisation | ₹1,426 crore |
| Enterprise value | ₹1,425 crore |
| P/E (TTM) | 0.00 |
| Price to book | 4.37 |
| Price to sales (TTM) | 2.70 |
| Book value per share | ₹112.96 |
| Dividend yield | 93.24% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Jan 02 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹520 crore | ₹78 crore | ₹58 crore | 0.00 |
| Mar 2025 | ₹470 crore | ₹69 crore | ₹51 crore | 17.58 |
| Mar 2024 | ₹438 crore | ₹62 crore | ₹45 crore | 15.50 |
| Mar 2023 | ₹394 crore | ₹54 crore | ₹40 crore | 13.63 |
| Mar 2022 | ₹421 crore | ₹91 crore | ₹67 crore | 23.00 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 46.5% |
|---|---|
| Foreign institutions (FII) | 2.4% |
| Mutual funds | 5.8% |
| Other domestic institutions | 6.5% |
| Retail and others | 38.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.